Member Info for Chelsea11

Many laughing emojis

An investor with a scientific bias who didn’t know Avidimab was used in the Covidity project?

Really? It was in formal company communications.

Looks on paper like a very solid addition to the team at Scancell. Wonder how that role does, or doesn’t, fit in with the Head of Development (Callum Scott).

HAGW

Greenshaw - do you understand what AI returned to you? You don’t do you and therefore your post is just clutter, pointless and adds absolutely zero value.

Here’s hoping no one will ever be able to create a digital version of my Mother-in-Law.

The total obsession with AI from some posters here is very dangerous imo.

Might as well ask it to confirm when the SP will be 8 quid.

In respect of vaccine’s & healthcare, far more of a concern than the orange one is Vance imo. Another total lunatic taking over the asylum. I also wonder just how much longer he will remain in Trumps shadow.

RichP - agree. The long term track record of profitable growth being a mix of both organic and acquired.

Scope Trial results + deal is highly, highly unlikely imo.

Trial results in isolation.

Hopefully 120p+ is the new norm. Yet another year of solid growth and further acquisitions can be expected. Well done Begbies.

G https://www.thisismoney.co.uk/money/markets/article-14884855/Insolvency-firms-profits-double-larger-firms-fail.html?ico=mol_desktop_money-newtab&molReferrerUrl=https%3A%2F%2Fwww.dailymail.co.uk%2Fmoney%2Findex.html&_gl=1*3qk7jk*_gcl_au*MzYxNjYzMTU5LjE3NTE0MDEzNTg.*_ga*NDMxMTYyNzE5LjE3NTE0MDEzNTc.*_ga_C9F47K6NW6*czE3NTE5ODk0MDMkbzE1JGcxJHQxNzUxOTg5NTAzJGo0NiRsMCRoNjY3OTk4Mjgw

Looking both backwards and forwards, a great set of results.

Well done to all those who have continued to hold (and/or bought) and ignored the total nonsense spouted here from some, that there was little growth and that the acquisitions the company was making, were only a distraction. Couldn’t have been more wrong!

Chester - we’re looking pretty good for the 6-8 weeks we explicitly predicted at the start of June for SCOPE data (aligned to Company previously communicated indications). Was never going to be earlier than that.

Caveat - IMO 😂

Within the post period update:

“H&H brands listed into CVS Pharmacy in the US”

CVS are the biggest pharmacy retailer in the US.

Imagine the agitation here on Sunday / Monday when we hit 34 degrees 😤😂

What a totally bizarre comment. Markets have been open just 45mins and the SP up +15%.

WOW! Not sure it could have been any better than that.

Cannot wait to see how the market responds. 40p incoming?

Cutting through all of this……….

- There was no bad news meaning delays in SCOPE trial data (which could have happened). In fact the opposite is true ie. up to the minute confirmation that data will be made available at the precise time the company previously said it will be made available.

- the GlyMab platform is becoming increasingly high profile and again, there has been no bad news ie. Genmab dropping SCLP products.

Bad news can land at any time in the lifecycle of a company. It didn’t land here today and therefore there can only be optimism for the future.

Https://www.proactiveinvestors.com/companies/news/1073568/scancell-advances-cancer-immunotherapy-trial-with-new-dosing-approach-for-advanced-melanoma-1073568.html

Posted 21/06 (and previously).

“SCOPE data release timeline prediction now down to 2 to 6 weeks (from original 4 to 8)”

IMO.

Suspect they might say they’re not on the Titanic and have no deckchairs to rearrange.